for people ages 18 years and up (full criteria)
at Sacramento, California and other locations
study started
estimated completion
Principal Investigator
by Edward Kim, MD, PhD



Open-label, dose escalation, multi-center, Phase I / II study to assess the safety of an autologous T-cell product (ET140203) in adult subjects with Alpha-fetoprotein (AFP)-positive/Human Leukocyte Antigen (HLA) A-2-positive advanced hepatocellular carcinoma (HCC).

Official Title

An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140203 T Cells and Determine the Recommended Phase II Dose (RP2D) in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-1)


The purpose of this study is to investigate an autologous T-cell therapy for advanced hepatocellular carcinoma (HCC). ET140203 T cells are autologous T cells genetically modified to carry a TCR-mimic (TCRm) construct capable of mediating cell killing by targeting tumor specific intracellular antigens and addressing solid tumor therapy challenges.


Hepatocellular Carcinoma Liver Cancer Liver Neoplasm Metastatic Liver Cancer Hepatocellular Carcinoma HCC Advanced HCC Late-Stage HCC Metastatic HCC T-cell therapy Immunotherapy Carcinoma Carcinoma, Hepatocellular Liver Neoplasms ET140203 autologous T cell product ET140203 TCells


You can join if…

Open to people ages 18 years and up

  • Histologically confirmed HCC with serum AFP >200ng/ml at time of screening and following most current line of therapy OR radiographic diagnosis of HCC with serum AFP >400ng/ml at time of screening and following most current line of therapy.
  • Metastatic or locally advanced, unresectable HCC
  • Must have failed or not tolerated at least two (2) different anti-HCC systemic agents
  • Molecular Human Leukocyte Antigen ("HLA") class I allele typing confirms participant carries at least one HLA-A2 allele
  • Life expectancy of at least 4 months
  • Karnofsky Performance Scale greater than or equal to 70
  • At least 1 measurable lesion on imaging by RECIST
  • Child-Pugh A or B7
  • Absolute neutrophil count greater than or equal to 1,500/mm3

  • Platelet count greater than or equal to 60,000/mm3

You CAN'T join if...

  • Clinically significant cardiac disease
  • Clinically significant pre-existing illness or active infection
  • Clinically significant Central Nervous System (CNS) or neural dysfunction
  • Active autoimmune disease requiring therapy
  • Active malignancy other than HCC unless expected survival is greater than or equal to three years without any treatment (exception: hormone/androgen-deprivation therapy) and without any organ involvement
  • History of organ transplant
  • Compromised circulation in portal vein, hepatic vein, or vena cava due to obstruction
  • Advanced HCC involving greater than one-third of the liver


  • UC Davis accepting new patients
    Sacramento California 95817 United States
  • City of Hope Medical Center accepting new patients
    Duarte California 91010 United States

Lead Scientist at UC Davis

  • Edward Kim, MD, PhD
    Associate Professor, Hematology and Oncology. Authored (or co-authored) 30 research publications.


accepting new patients
Start Date
Completion Date
Eureka Therapeutics Inc.
Sign up for this study
Phase 1/2
Study Type
Last Updated